Tirzepatide, a dual GIP/GLP-1 agonist, showed up to 20.9% average weight loss in SURMOUNT-1 at 72 weeks
21 % calories consumed on average by adults on GLP-1 medications, according to a KPMG analysis cited by CNBC
August 26, 2023 Additional Live Streams Top Stories Top Stories Suspect in deadly Berlin Pride attack shot and killed by police Jul 26, 2026 Trump weighs Iran options after two weeks of intense strikes Jul 26, 2026 Netanyahu, Zelenskyy set for high-profile visits to DC Jul 26, 2026 Record crowds at the WNBA All-Star game Jul 26, 2026 Houthis attack ships in the Red Sea, raising concerns over widening conflict Jul 26, 2026 How likely will the US launch a massive attack against Iran
Mahsa Tehrani, MD Rheumatologist What are they saying about VitaFusion Doctors & Wellness Center in Alexandria, VA I came with sciatica pain and had laser treatment as my doctor suggested and felt much better
Tennessee permits telehealth prescribing for weight loss medications